Veeva Systems Inc. reports developments in cloud software, data, AI, and consulting for the life sciences industry. Company news commonly covers adoption of the Veeva Vault Platform, including Development Cloud, Quality Cloud, Commercial Cloud, Data Cloud, Vault CRM, and Veeva MedTech applications for clinical, regulatory, quality, commercial, and medical operations.
Updates also include customer standardization projects with pharmaceutical, biotechnology, medical device, and diagnostics companies; product and data offerings such as Link Key People and Veeva AI; fiscal results and subscription revenue trends; and corporate actions such as acquisitions, including the completed purchase of Ostro as a life sciences brand engagement platform.
Veeva Systems (NYSE: VEEV) announced that three of the top ten biopharmaceutical companies utilize its Veeva Link Scientific Awareness platform, which provides real-time insights into product awareness and sentiment. This tool enhances the ability of medical teams to refine product strategies and communicate effectively with the scientific community. Veeva Link offers comprehensive analysis from over 300,000 medical congresses and 100 million social media posts, fostering value-driven medical activities. The platform is available in 87 countries and is designed to keep pace with the evolving healthcare landscape.
Veeva Systems (NYSE: VEEV) released its Veeva Pulse Field Trends Report, revealing that U.S. healthcare professional (HCP) access now averages 60%, with key specialties nearing 80%. The report highlights that over 50% of accessible HCPs engage via video, generating 3x promotional response compared to in-person only. Additionally, half of accessible HCPs limit engagements to three companies or less. Companies can leverage this data to optimize field strategies and enhance engagement efficiency, ultimately driving better outcomes in the biopharma industry.
Veeva Systems (NYSE: VEEV) will announce its third quarter financial results on December 1, 2022, following the close of the market. The results will cover the period ending October 31, 2022. A conference call and webcast will take place at 2:00 p.m. PT (5:00 p.m. ET) the same day to discuss these results. Investors can access prepared remarks on Veeva's investor relations website at 1:05 p.m. PT (4:05 p.m. ET). A replay of the webcast will be available afterward.
Veeva Systems (NYSE: VEEV) has announced a ten-year strategic partnership with Merck (NYSE: MRK), building upon their existing 12-year collaboration. The agreement entails Merck adopting a Veeva-first approach for new software and data solutions, aimed at reducing operational costs and enhancing patient and healthcare professional experiences. Veeva will offer a strategic pricing model and seek Merck's input on product development. This partnership is designed to accelerate Merck's digital transformation and improve efficiency in utilizing Veeva’s integrated platform.
Veeva Systems has launched Veeva Vault CRM for Medtech, a new unified CRM and content management application tailored for medtech sales teams and medical affairs professionals. This solution allows medtech companies to efficiently manage customer relationships and content without extensive customizations. Key features include inventory management, surgical case management, and stakeholder navigation. This application aims to enhance collaboration and streamline business processes across commercial and medical teams.
Veeva Systems (NYSE: VEEV) announced the launch of Veeva CDB, a new solution designed to streamline clinical data management by aggregating and transforming data from various sources. This platform aims to reduce complexity and costs in clinical trial data handling, allowing for centralized data query resolution and improved trial execution speed. Veeva CDB has supported over 100 trials, enhancing data visibility and enabling faster decision-making. It also introduces a Data Provider Program to standardize data delivery among sponsors, CROs, and providers.
Veeva Systems (NYSE: VEEV) unveiled Veeva ePRO on October 18, 2022, enhancing patient-centric digital trials. This application streamlines patient assessments via mobile devices and web browsers, enabling sponsors and research sites to access real-time data. Addressing challenges like lengthy trial participation and redundant data entry, Veeva ePRO improves patient experience. Integrated within the Veeva Vault Clinical Suite, it facilitates seamless communication and tracking, offering benefits for both patients and trial sponsors.
On October 17, 2022, Veeva Systems (NYSE: VEEV) announced that 40 contract research organizations (CROs), including four of the top six global CROs, have adopted the Veeva Vault CTMS to enhance clinical trial efficiency. This solution is now used by over 120 sponsors, including nine of the top 20 pharmaceutical companies, establishing it as the industry leader in clinical trial management. The Vault CTMS provides a comprehensive view of trial metrics, improving collaboration and study performance, which is essential for accelerating trial processes.
Veeva Systems (NYSE: VEEV) announced the launch of two new applications, Link SiteBase and Link TrialBase, aimed at enhancing clinical trial design and site selection. Set for release in April and October 2023, respectively, Link SiteBase helps identify and rank research sites, while Link TrialBase provides critical clinical trial intelligence. The innovations are designed to address challenges in trial execution, such as intense competition and protocol complexity, delivering comprehensive data to speed up trial outcomes.
Veeva Systems (NYSE: VEEV) announced that over 350 companies are leveraging its Veeva Vault RIM Suite applications to enhance regulatory processes. In the past year, more than 65 emerging biotechs adopted these solutions to improve submission planning and compliance with evolving regulations. Notable advancements include Active Dossier management, label change tracking, and non-eCTD electronic publishing. A top 20 pharma streamlined 19 million data points through the platform, reducing SOPs by 90%. The suite's new features aim to accelerate time to market for submissions.